Table III.
Association of BRAF gene mutation with clinicopathological features.
| Characteristics | BRAF wide-type (n=752) n (%) | BRAF V600E mut (n=147) n (%) | BRAF 594 or 596 mut (n=13) n (%) | P-valuea | P-valueb | P-valuec |
|---|---|---|---|---|---|---|
| Sex | 0.091 | 0.109 | 0.303 | |||
| Male | 397 (52.8) | 67 (45.6) | 4 (30.8) | |||
| Female | 355 (47.2) | 80 (54.4) | 9 (69.2) | |||
| Age (years) | <0.001 | <0.001 | 0.017 | |||
| Median | 55 | 49 | 58 | |||
| Range | 7–92 | 7–84 | 25–75 | |||
| Subtype | <0.001 | <0.001 | <0.001 | |||
| Acral | 395 (52.5) | 58 (39.5) | 3 (23.1) | |||
| Mucosal | 208 (27.7) | 14 (9.5) | 7 (53.8) | |||
| Non-acral cutaneous | 149 (19.8) | 75 (51) | 3 (23.1) | |||
| Clinical stage | <0.001 | <0.001 | 0.801 | |||
| I | 8 (1.1) | 2 (1.4) | 0 (0) | |||
| II | 439 (58.4) | 39 (26.5) | 5 (38.5) | |||
| III | 165 (21.9) | 29 (19.7) | 2 (15.4) | |||
| IV | 140 (18.6) | 77 (52.4) | 6 (46.2) | |||
| Ulceration | 0.034 | 0.030 | 0.043 | |||
| Yes | 426 (56.6) | 90 (66.7) | 5 (38.5) | |||
| No | 326 (43.4) | 45 (33.3) | 8 (61.5) | |||
| Thickness (mm) | 0.017 | 0.008 | 0.124 | |||
| ≤1.0 | 71 (9.4) | 12 (8.2) | 0 (0) | |||
| 1.1–2.0 | 86 (11.4) | 9 (6.1) | 3 (23.1) | |||
| 2.1–4.0 | 196 (26.1) | 26 (17.7) | 2 (15.4) | |||
| >4.0 | 399 (53.1) | 100 (6.8) | 8 (61.5) |
a
Comparison of the three groups (BRAF wild-type versus BRAF V600E mut versus BRAF 594 or 596 mut).
b
Comparison of BRAF wild-type versus BRAF V600E mut.
c
Comparison of BRAF V600E mut versus BRAF 594 or 596 mut.